FY2018 Earnings Forecast for ImmunoGen, Inc. Issued By Cantor Fitzgerald (IMGN)

ImmunoGen, Inc. (NASDAQ:IMGN) – Research analysts at Cantor Fitzgerald upped their FY2018 earnings per share (EPS) estimates for shares of ImmunoGen in a report released on Monday. Cantor Fitzgerald analyst M. Goldstein now expects that the biotechnology company will post earnings of ($1.03) per share for the year, up from their previous estimate of ($1.08). Cantor Fitzgerald has a “Hold” rating and a $5.00 price objective on the stock.

ImmunoGen (NASDAQ:IMGN) last announced its quarterly earnings results on Friday, February 9th. The biotechnology company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.03). The business had revenue of $39.40 million for the quarter, compared to the consensus estimate of $39.62 million. During the same quarter in the prior year, the firm earned ($0.39) EPS. The company’s revenue for the quarter was up 185.5% compared to the same quarter last year.

Several other brokerages have also commented on IMGN. Royal Bank of Canada restated an “outperform” rating and issued a $12.00 price target on shares of ImmunoGen in a research note on Thursday, February 8th. HC Wainwright set a $18.00 price objective on shares of ImmunoGen and gave the company a “buy” rating in a research note on Monday. BidaskClub upgraded shares of ImmunoGen from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 9th. Finally, Zacks Investment Research upgraded shares of ImmunoGen from a “hold” rating to a “buy” rating and set a $6.50 price objective on the stock in a research note on Tuesday, October 31st. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. ImmunoGen presently has a consensus rating of “Buy” and a consensus target price of $9.10.

Shares of ImmunoGen (NASDAQ IMGN) traded down $0.74 during trading hours on Wednesday, hitting $9.80. 5,240,200 shares of the company’s stock traded hands, compared to its average volume of 3,302,446. ImmunoGen has a 12 month low of $2.40 and a 12 month high of $10.66. The firm has a market capitalization of $1,394.58, a price-to-earnings ratio of -9.61 and a beta of 2.50. The company has a quick ratio of 2.78, a current ratio of 2.81 and a debt-to-equity ratio of -0.03.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Schwab Charles Investment Management Inc. increased its stake in shares of ImmunoGen by 0.6% during the second quarter. Schwab Charles Investment Management Inc. now owns 331,898 shares of the biotechnology company’s stock valued at $2,360,000 after acquiring an additional 1,919 shares during the period. Royal Bank of Canada grew its position in ImmunoGen by 789.0% in the second quarter. Royal Bank of Canada now owns 154,432 shares of the biotechnology company’s stock worth $1,098,000 after buying an additional 137,061 shares during the last quarter. Chicago Equity Partners LLC grew its position in ImmunoGen by 124.7% in the third quarter. Chicago Equity Partners LLC now owns 490,635 shares of the biotechnology company’s stock worth $3,753,000 after buying an additional 272,315 shares during the last quarter. Bank of Nova Scotia acquired a new position in ImmunoGen in the second quarter worth approximately $591,000. Finally, OxFORD Asset Management LLP acquired a new position in ImmunoGen in the second quarter worth approximately $506,000. Institutional investors and hedge funds own 67.97% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “FY2018 Earnings Forecast for ImmunoGen, Inc. Issued By Cantor Fitzgerald (IMGN)” was reported by American Banking News and is the property of of American Banking News. If you are accessing this article on another domain, it was stolen and reposted in violation of United States and international trademark & copyright legislation. The original version of this article can be accessed at https://www.americanbankingnews.com/2018/02/14/fy2018-earnings-forecast-for-immunogen-inc-issued-by-cantor-fitzgerald-imgn.html.

About ImmunoGen

ImmunoGen, Inc is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. An ADC with the Company’s technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target.

Earnings History and Estimates for ImmunoGen (NASDAQ:IMGN)

Receive News & Ratings for ImmunoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoGen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply